Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbohydrate digestion enzymes represent a group of hydrolases responsible for breaking down complex dietary polysaccharides and oligosaccharides into absorbable monosaccharides. This group primarily includes salivary and pancreatic alpha-amylase, which initiate starch degradation, and the brush-border disaccharidases such as maltase-glucoamylase, sucrase-isomaltase, and lactase. In a therapeutic context, these enzymes are major targets for the management of type 2 diabetes mellitus. By inhibiting these enzymes, particularly alpha-glucosidase, the rate of carbohydrate digestion is slowed, leading to a delayed and reduced rise in postprandial blood glucose levels. While effective for glycemic control, pharmacological modulation of these enzymes often results in gastrointestinal side effects due to the fermentation of undigested carbohydrates by colonic bacteria.
Competitive inhibition of membrane-bound intestinal alpha-glucoside hydrolase enzymes and pancreatic alpha-amylase, which delays the absorption of glucose and reduces postprandial blood glucose excursions.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carbohydrate digestion enzymes.